$IOVA $2 to $14 | Holy Grail of Cancer Therapy

Avi Mash hosts Iovance ($IOVA) investor Minnesota Gopher and trader Father of Trades to discuss Iovance's IL-12 tethered TIL program, Amtagvi data in melanoma, non small cell lung cancer, endometrial cancer and sarcoma, FDA CNPV vouchers, a possible Merck buyout, and short selling in biotech. Father of Trades reviews the $IOVA chart and options chain and compares it to $SLS. Minnesota Gopher expects 18 to 22 by year end, and over 30 if a voucher basket is accepted. This podcast is powered by Scanley, AI visibility for banks and credit unions. Get your 1st month free with code DAILYSTACK at https://meetscanley.com Taking a BTC loan? Our friends at Ledn are offering .25% off their lowest rates with our link: https://www.ledn.io/partner/dailystack Chapters: 0:00 Intro music 4:43 Minnesota Gopher on $IOVA and biotech short selling 15:37 IL-12 tethered TIL: holy grail of cancer therapy 22:19 Amtagvi frontline push and Keytruda style expansion 24:54 Biotech lagging the market and AI in medicine 29:06 FDA timelines, China drugs and CNPV vouchers 36:08 Iovance buyout, Merck and global distribution 44:04 Lung, melanoma, endometrial and sarcoma TIL data 56:23 $IOVA chart, volume profile and key levels 1:04:10 $IOVA options chain, open interest and gamma ramp 1:14:45 $IOVA price targets and the $SLS comparison 1:24:21 Father of Trades on BlackBerry QNX and holding winners Key takeaways: \- Minnesota Gopher calls Iovance's IL-12 tethered TIL a potential holy grail because, in his view, it could turn cold tumors hot and make them treatable. \- Minnesota Gopher cited company figures: a 64.3% response rate in EGFR non small cell lung cancer with Keytruda and a 65.2% response rate in frontline melanoma with Keytruda. \- Minnesota Gopher believes Iovance's new FDA and regulatory hires point to a basket submission for CNPV vouchers in non small cell lung cancer, endometrial cancer and sarcoma, and he named Merck as the likeliest acquirer. \- Father of Trades read the options chain as pinning $IOVA near $14 in the short term and said a move above $20 could set up a gamma squeeze, as he saw in $SLS. \- Father of Trades said scalping profits should be parked in high conviction companies and gains should be protected by taking back cost basis on 10x or 15x winners. Listen and follow The Daily Stack: Spotify: https://open.spotify.com/show/0JQzqfVmkKiXuwSA6hyoDs Apple Podcasts: https://podcasts.apple.com/us/podcast/the-daily-stack/id1831884653 Website: https://dailystackhq.com X: https://x.com/dailystackHQ Not financial advice.